Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma
Active, not recruiting
This phase I clinical trial studies the side effects and best dose of lenalidomide and
ibrutinib when given together with rituximab in treating patients with previously untreated
stage II-IV follicular lymphoma. Lenalidomide may stimulate the immune system in different
ways and stop cancer cells from growing. Ibrutinib may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as
rituximab, can find cancer cells and help kill them. Giving lenalidomide and ibrutinib
together with rituximab may work well in treating follicular lymphoma.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.